September 13, 2013 8:32 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Optimer Pharmaceuticals, Inc.(NASDAQ: OPTR) today announced the expiration of the waiting period under theHart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) in connectionwith the previously announced merger agreement under which Cubist will acquireall of the outstanding common stock of Optimer.Expiration of the HSR waiting period satisfies one of the conditions to theclosing of the merger. The proposed merger remains subject to approval by thestockholders of Optimer, as well as other customary closing conditions.Upon closing of the merger, each holder of Optimer common stock will receive$10.75 per share in cash, plus one Contingent Value Right, entitling theholder to receive an additional one-time cash payment of up to $5.00 for eachshare they own if certain net sales of DIFICID® (fidaxomicin) in the UnitedStates and Canada are achieved.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.